Review



galectin 3 inhibitor td139 provides neuroprotection  (Galectin Therapeutics)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Galectin Therapeutics galectin 3 inhibitor td139 provides neuroprotection
    Galectin 3 Inhibitor Td139 Provides Neuroprotection, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/galectin+3+inhibitor+td139/td139/10__1167_slash_tvst__15__1__11-244-12-12
    Average 86 stars, based on 1 article reviews
    galectin 3 inhibitor td139 provides neuroprotection - by Bioz Stars, 2026-08
    86/100 stars

    Images



    Similar Products

    galectin 3 inhibitor td139 provides neuroprotection  (Galectin Therapeutics)
    86
    Galectin Therapeutics galectin 3 inhibitor td139 provides neuroprotection
    Galectin 3 Inhibitor Td139 Provides Neuroprotection, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/galectin+3+inhibitor+td139/td139/10__1167_slash_tvst__15__1__11-244-12-12
    Average 86 stars, based on 1 article reviews
    galectin 3 inhibitor td139 provides neuroprotection - by Bioz Stars, 2026-08
    86/100 stars
    		  Buy from Supplier
    galectin 3 inhibitor td139  (Galectin Therapeutics)
    86
    Galectin Therapeutics galectin 3 inhibitor td139
    ( A ) Schematic diagram showing the protocol of <t>TD139</t> treatment. ( B ) Incidence of diabetes expressed as percentage of diabetic mice at different ages ( n = 20). ( C ) Glucose excursion curve after receiving IPGTT ( n = 8). ( D ) Serum insulin concentration at 0 and 15 min during the IPGTT in 12-week-old TD139 or vehicle-treated NOD mice ( n = 7 to 8). ( E ) Representative H&E staining of pancreas from 12-week-old NOD mice treated with TD139 or vehicle ( n = 4). ( F ) Insulitis scores calculated on the basis of histological evaluation of pancreatic section as in (E). ( G ) Frequencies of CD4 + and CD8 + T cells in total CD3 + T cells from islets of 12-week-old NOD mice treated with TD139 or vehicle ( n = 4). ( H ) Frequencies of T reg cells (CD4 + CD25 + FOXP3 + ) from islets of 12-week-old NOD mice treated with TD139 or vehicle ( n = 4). ( I to K ) Frequencies of perforin + CD8 + T, Tc1 (CD8 + IFN-γ + ), Tc2 (CD8 + IL-4 + ), Tc17 (CD8 + IL-17 + ), and granzyme B + CD8 + T subsets from islets of 12-week-old NOD mice treated with TD139 or vehicle ( n = 3 to 4). ( L ) Frequencies of T H 1 (CD4 + IFN-γ + ), T H 2 (CD4 + IL-4 + ), and T H 17 (CD4 + IL-17 + ) from islets of 12-week-old NOD mice treated with TD139 or vehicle ( n = 4). Data are expressed as mean ± SEM. *P < 0.05 and **P < 0.01.
    Galectin 3 Inhibitor Td139, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/galectin+3+inhibitor+td139/td139/pmc12757048-165-15-15
    Average 86 stars, based on 1 article reviews
    galectin 3 inhibitor td139 - by Bioz Stars, 2026-08
    86/100 stars
    		  Buy from Supplier
    galectin 3 with td139  (Galectin Therapeutics)
    86
    Galectin Therapeutics galectin 3 with td139
    ( A ) Schematic diagram showing the protocol of <t>TD139</t> treatment. ( B ) Incidence of diabetes expressed as percentage of diabetic mice at different ages ( n = 20). ( C ) Glucose excursion curve after receiving IPGTT ( n = 8). ( D ) Serum insulin concentration at 0 and 15 min during the IPGTT in 12-week-old TD139 or vehicle-treated NOD mice ( n = 7 to 8). ( E ) Representative H&E staining of pancreas from 12-week-old NOD mice treated with TD139 or vehicle ( n = 4). ( F ) Insulitis scores calculated on the basis of histological evaluation of pancreatic section as in (E). ( G ) Frequencies of CD4 + and CD8 + T cells in total CD3 + T cells from islets of 12-week-old NOD mice treated with TD139 or vehicle ( n = 4). ( H ) Frequencies of T reg cells (CD4 + CD25 + FOXP3 + ) from islets of 12-week-old NOD mice treated with TD139 or vehicle ( n = 4). ( I to K ) Frequencies of perforin + CD8 + T, Tc1 (CD8 + IFN-γ + ), Tc2 (CD8 + IL-4 + ), Tc17 (CD8 + IL-17 + ), and granzyme B + CD8 + T subsets from islets of 12-week-old NOD mice treated with TD139 or vehicle ( n = 3 to 4). ( L ) Frequencies of T H 1 (CD4 + IFN-γ + ), T H 2 (CD4 + IL-4 + ), and T H 17 (CD4 + IL-17 + ) from islets of 12-week-old NOD mice treated with TD139 or vehicle ( n = 4). Data are expressed as mean ± SEM. *P < 0.05 and **P < 0.01.
    Galectin 3 With Td139, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/galectin+3+inhibitor+td139/td139/pmc12625987-16-7-7
    Average 86 stars, based on 1 article reviews
    galectin 3 with td139 - by Bioz Stars, 2026-08
    86/100 stars
    		  Buy from Supplier
    td139 (galectin-3 inhibitor)  (Galectin Therapeutics)
    90
    Galectin Therapeutics td139 (galectin-3 inhibitor)
    ( A ) Schematic diagram showing the protocol of <t>TD139</t> treatment. ( B ) Incidence of diabetes expressed as percentage of diabetic mice at different ages ( n = 20). ( C ) Glucose excursion curve after receiving IPGTT ( n = 8). ( D ) Serum insulin concentration at 0 and 15 min during the IPGTT in 12-week-old TD139 or vehicle-treated NOD mice ( n = 7 to 8). ( E ) Representative H&E staining of pancreas from 12-week-old NOD mice treated with TD139 or vehicle ( n = 4). ( F ) Insulitis scores calculated on the basis of histological evaluation of pancreatic section as in (E). ( G ) Frequencies of CD4 + and CD8 + T cells in total CD3 + T cells from islets of 12-week-old NOD mice treated with TD139 or vehicle ( n = 4). ( H ) Frequencies of T reg cells (CD4 + CD25 + FOXP3 + ) from islets of 12-week-old NOD mice treated with TD139 or vehicle ( n = 4). ( I to K ) Frequencies of perforin + CD8 + T, Tc1 (CD8 + IFN-γ + ), Tc2 (CD8 + IL-4 + ), Tc17 (CD8 + IL-17 + ), and granzyme B + CD8 + T subsets from islets of 12-week-old NOD mice treated with TD139 or vehicle ( n = 3 to 4). ( L ) Frequencies of T H 1 (CD4 + IFN-γ + ), T H 2 (CD4 + IL-4 + ), and T H 17 (CD4 + IL-17 + ) from islets of 12-week-old NOD mice treated with TD139 or vehicle ( n = 4). Data are expressed as mean ± SEM. *P < 0.05 and **P < 0.01.
    Td139 (Galectin 3 Inhibitor), supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/galectin+3+inhibitor+td139/td139/pm40649005-321-7-8
    Average 90 stars, based on 1 article reviews
    td139 (galectin-3 inhibitor) - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    galectin-3 inhibitor td139  (Galectin Therapeutics)
    90
    Galectin Therapeutics galectin-3 inhibitor td139
    ( A ) Schematic diagram showing the protocol of <t>TD139</t> treatment. ( B ) Incidence of diabetes expressed as percentage of diabetic mice at different ages ( n = 20). ( C ) Glucose excursion curve after receiving IPGTT ( n = 8). ( D ) Serum insulin concentration at 0 and 15 min during the IPGTT in 12-week-old TD139 or vehicle-treated NOD mice ( n = 7 to 8). ( E ) Representative H&E staining of pancreas from 12-week-old NOD mice treated with TD139 or vehicle ( n = 4). ( F ) Insulitis scores calculated on the basis of histological evaluation of pancreatic section as in (E). ( G ) Frequencies of CD4 + and CD8 + T cells in total CD3 + T cells from islets of 12-week-old NOD mice treated with TD139 or vehicle ( n = 4). ( H ) Frequencies of T reg cells (CD4 + CD25 + FOXP3 + ) from islets of 12-week-old NOD mice treated with TD139 or vehicle ( n = 4). ( I to K ) Frequencies of perforin + CD8 + T, Tc1 (CD8 + IFN-γ + ), Tc2 (CD8 + IL-4 + ), Tc17 (CD8 + IL-17 + ), and granzyme B + CD8 + T subsets from islets of 12-week-old NOD mice treated with TD139 or vehicle ( n = 3 to 4). ( L ) Frequencies of T H 1 (CD4 + IFN-γ + ), T H 2 (CD4 + IL-4 + ), and T H 17 (CD4 + IL-17 + ) from islets of 12-week-old NOD mice treated with TD139 or vehicle ( n = 4). Data are expressed as mean ± SEM. *P < 0.05 and **P < 0.01.
    Galectin 3 Inhibitor Td139, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/galectin+3+inhibitor+td139/td139/pm40573209-238-3-3
    Average 90 stars, based on 1 article reviews
    galectin-3 inhibitor td139 - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier
    small-molecule galectin-3 inhibitor td139  (Galectin Therapeutics)
    90
    Galectin Therapeutics small-molecule galectin-3 inhibitor td139
    ( A ) Schematic diagram showing the protocol of <t>TD139</t> treatment. ( B ) Incidence of diabetes expressed as percentage of diabetic mice at different ages ( n = 20). ( C ) Glucose excursion curve after receiving IPGTT ( n = 8). ( D ) Serum insulin concentration at 0 and 15 min during the IPGTT in 12-week-old TD139 or vehicle-treated NOD mice ( n = 7 to 8). ( E ) Representative H&E staining of pancreas from 12-week-old NOD mice treated with TD139 or vehicle ( n = 4). ( F ) Insulitis scores calculated on the basis of histological evaluation of pancreatic section as in (E). ( G ) Frequencies of CD4 + and CD8 + T cells in total CD3 + T cells from islets of 12-week-old NOD mice treated with TD139 or vehicle ( n = 4). ( H ) Frequencies of T reg cells (CD4 + CD25 + FOXP3 + ) from islets of 12-week-old NOD mice treated with TD139 or vehicle ( n = 4). ( I to K ) Frequencies of perforin + CD8 + T, Tc1 (CD8 + IFN-γ + ), Tc2 (CD8 + IL-4 + ), Tc17 (CD8 + IL-17 + ), and granzyme B + CD8 + T subsets from islets of 12-week-old NOD mice treated with TD139 or vehicle ( n = 3 to 4). ( L ) Frequencies of T H 1 (CD4 + IFN-γ + ), T H 2 (CD4 + IL-4 + ), and T H 17 (CD4 + IL-17 + ) from islets of 12-week-old NOD mice treated with TD139 or vehicle ( n = 4). Data are expressed as mean ± SEM. *P < 0.05 and **P < 0.01.
    Small Molecule Galectin 3 Inhibitor Td139, supplied by Galectin Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/galectin+3+inhibitor+td139/td139/pmc12063347-18-2-3
    Average 90 stars, based on 1 article reviews
    small-molecule galectin-3 inhibitor td139 - by Bioz Stars, 2026-08
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A ) Schematic diagram showing the protocol of TD139 treatment. ( B ) Incidence of diabetes expressed as percentage of diabetic mice at different ages ( n = 20). ( C ) Glucose excursion curve after receiving IPGTT ( n = 8). ( D ) Serum insulin concentration at 0 and 15 min during the IPGTT in 12-week-old TD139 or vehicle-treated NOD mice ( n = 7 to 8). ( E ) Representative H&E staining of pancreas from 12-week-old NOD mice treated with TD139 or vehicle ( n = 4). ( F ) Insulitis scores calculated on the basis of histological evaluation of pancreatic section as in (E). ( G ) Frequencies of CD4 + and CD8 + T cells in total CD3 + T cells from islets of 12-week-old NOD mice treated with TD139 or vehicle ( n = 4). ( H ) Frequencies of T reg cells (CD4 + CD25 + FOXP3 + ) from islets of 12-week-old NOD mice treated with TD139 or vehicle ( n = 4). ( I to K ) Frequencies of perforin + CD8 + T, Tc1 (CD8 + IFN-γ + ), Tc2 (CD8 + IL-4 + ), Tc17 (CD8 + IL-17 + ), and granzyme B + CD8 + T subsets from islets of 12-week-old NOD mice treated with TD139 or vehicle ( n = 3 to 4). ( L ) Frequencies of T H 1 (CD4 + IFN-γ + ), T H 2 (CD4 + IL-4 + ), and T H 17 (CD4 + IL-17 + ) from islets of 12-week-old NOD mice treated with TD139 or vehicle ( n = 4). Data are expressed as mean ± SEM. *P < 0.05 and **P < 0.01.

    Journal: Science Advances

    Article Title: Galectin-3 exacerbates autoimmune diabetes by limiting regulatory T cell differentiation and function

    doi: 10.1126/sciadv.adz7916

    Figure Lengend Snippet: ( A ) Schematic diagram showing the protocol of TD139 treatment. ( B ) Incidence of diabetes expressed as percentage of diabetic mice at different ages ( n = 20). ( C ) Glucose excursion curve after receiving IPGTT ( n = 8). ( D ) Serum insulin concentration at 0 and 15 min during the IPGTT in 12-week-old TD139 or vehicle-treated NOD mice ( n = 7 to 8). ( E ) Representative H&E staining of pancreas from 12-week-old NOD mice treated with TD139 or vehicle ( n = 4). ( F ) Insulitis scores calculated on the basis of histological evaluation of pancreatic section as in (E). ( G ) Frequencies of CD4 + and CD8 + T cells in total CD3 + T cells from islets of 12-week-old NOD mice treated with TD139 or vehicle ( n = 4). ( H ) Frequencies of T reg cells (CD4 + CD25 + FOXP3 + ) from islets of 12-week-old NOD mice treated with TD139 or vehicle ( n = 4). ( I to K ) Frequencies of perforin + CD8 + T, Tc1 (CD8 + IFN-γ + ), Tc2 (CD8 + IL-4 + ), Tc17 (CD8 + IL-17 + ), and granzyme B + CD8 + T subsets from islets of 12-week-old NOD mice treated with TD139 or vehicle ( n = 3 to 4). ( L ) Frequencies of T H 1 (CD4 + IFN-γ + ), T H 2 (CD4 + IL-4 + ), and T H 17 (CD4 + IL-17 + ) from islets of 12-week-old NOD mice treated with TD139 or vehicle ( n = 4). Data are expressed as mean ± SEM. *P < 0.05 and **P < 0.01.

    Article Snippet: Our findings suggest a promising avenue for potential therapeutic targets of T1D and introduce the Galectin-3 inhibitor TD139, as a potent antidiabetic drug, to prevent and treat T1D.

    Techniques: Concentration Assay, Staining